Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H46O2 |
Molecular Weight | 366.6208 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O
InChI
InChIKey=GWHCXVQVJPWHRF-KTKRTIGZSA-N
InChI=1S/C24H46O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24(25)26/h9-10H,2-8,11-23H2,1H3,(H,25,26)/b10-9-
Molecular Formula | C24H46O2 |
Molecular Weight | 366.6208 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Nervonic acid is a long chain unsaturated fatty acid that is enriched in sphingomyelin. It consists of choline, sphingosine, phosphoric acid, and fatty acid. Nervonic acid may enhance the brain functions and prevent demyelination (Chemical Land21). Research shows that there is negative relationship between nervonic acid and obesity-related risk factors. Demyelination in adrenoleukodystrophy (ALD) is associated with an accumulation of very long chain saturated fatty acids stemming from a genetic defect in the peroxisomal beta oxidation system responsible for the chain shortening of these fatty acids. Sphingolipids from post mortem ALD brain have decreased levels of nervonic acid, 24:1(n-9), and increased levels of stearic acid, 18:0. Nervonic acid (C24:1), a component of membrane sphingolipids and phosphatidylethanolamines, may be a useful predictor of chronic kidney disease mortality and diabetes. Nervonic acid oils are being studied for pharmaceutical, nutraceutical and industrial applications. Nervonic acid is a major component of Lunaria oil. There is increasing evidence that dietary supplementation with nervonic acid is healthy for babies and infants during the early stage of brain development. Nervonic acid has been reported to reduce the shaking associated with Parkinson’s disease and the numbness caused by multiple sclerosis. It also has potential for treating schizophrenia and reducing early Alzheimer’s symptoms.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4343 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9367179 |
4.0 µM [Ki] | ||
Target ID: 534848.0 Gene Symbol: POLA1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9367179 |
0.3 µM [Ki] | ||
1.2 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Relationships between serum unsaturated fatty acids and coronary risk factors: negative relations between nervonic acid and obesity-related risk factors. | 2005 Nov |
|
Arachidonic acid predominates in the membrane phosphoglycerides of the early and term human placenta. | 2005 Nov |
|
Serum lipid fatty acids and temporal processing acuity in children with oral clefts. | 2006 Apr |
|
Serum phospholipid fatty acids, adipose tissue, and metabolic markers in obese adolescents. | 2006 Nov |
|
Site-directed mutational analysis of structural interactions of low molecule compounds binding to the N-terminal 8 kDa domain of DNA polymerase beta. | 2006 Nov 10 |
Sample Use Guides
Since Nervonic acid is almost insoluble in water, it often sold in the form of capsules. Generally speaking, two capsules orally every time, and two doses or two times a day, one in the morning, and the other in the evening. The recommended dosage ranges from 200mg to 300mg of pure nervonic acid.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9367179
Nervonic acid (NA) most effectively inhibited calf DNA polymerase a activity; its
minimum inhibitory concentration MIC was 2 uM. NA 10 uM completely suppressed the activities of both polymerases (calf DNA polymerase a and rat DNA polymerase b).
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:14:21 GMT 2023
by
admin
on
Sat Dec 16 05:14:21 GMT 2023
|
Record UNII |
91OQS788BE
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
3247 (Number of products:9)
Created by
admin on Sat Dec 16 05:14:21 GMT 2023 , Edited by admin on Sat Dec 16 05:14:21 GMT 2023
|
||
|
NCI_THESAURUS |
C68423
Created by
admin on Sat Dec 16 05:14:21 GMT 2023 , Edited by admin on Sat Dec 16 05:14:21 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C68395
Created by
admin on Sat Dec 16 05:14:21 GMT 2023 , Edited by admin on Sat Dec 16 05:14:21 GMT 2023
|
PRIMARY | NCIT | ||
|
300000015660
Created by
admin on Sat Dec 16 05:14:21 GMT 2023 , Edited by admin on Sat Dec 16 05:14:21 GMT 2023
|
PRIMARY | |||
|
506-37-6
Created by
admin on Sat Dec 16 05:14:21 GMT 2023 , Edited by admin on Sat Dec 16 05:14:21 GMT 2023
|
PRIMARY | |||
|
DTXSID80100930
Created by
admin on Sat Dec 16 05:14:21 GMT 2023 , Edited by admin on Sat Dec 16 05:14:21 GMT 2023
|
PRIMARY | |||
|
44247
Created by
admin on Sat Dec 16 05:14:21 GMT 2023 , Edited by admin on Sat Dec 16 05:14:21 GMT 2023
|
PRIMARY | |||
|
NERVONIC ACID
Created by
admin on Sat Dec 16 05:14:21 GMT 2023 , Edited by admin on Sat Dec 16 05:14:21 GMT 2023
|
PRIMARY | |||
|
5281120
Created by
admin on Sat Dec 16 05:14:21 GMT 2023 , Edited by admin on Sat Dec 16 05:14:21 GMT 2023
|
PRIMARY | |||
|
91OQS788BE
Created by
admin on Sat Dec 16 05:14:21 GMT 2023 , Edited by admin on Sat Dec 16 05:14:21 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |